A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic cancer after FOLFIRINOX failure.

开始日期2018-10-16

申办/合作机构

杏国新药股份有限公司

NCT03002103

/ Suspended临床3期

An Open-label, Randomized, Controlled Phase III Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

This is a prospective, multicenter, open-label, randomized, and controlled trial to test the superiority of EndoTAG®-1 in combination with paclitaxel and gemcitabine versus paclitaxel in combination with gemcitabine.
An independent data safety monitoring board (DSMB) will be established to decide on the recommended dose (RD) of EndoTAG®-1, paclitaxel and gemcitabine to be used throughout the trial and to monitor the patients' safety and treatment efficacy data

开始日期2016-11-23

申办/合作机构

杏国新药股份有限公司

100 项与 EndoTAG-1 相关的临床结果

登录后查看更多信息

100 项与 EndoTAG-1 相关的转化医学

登录后查看更多信息

100 项与 EndoTAG-1 相关的专利（医药）

登录后查看更多信息

项与 EndoTAG-1 相关的文献（医药）

2025-03-01·Current pharmaceutical biotechnology

Nanotheranostics: A Cutting-edge Technology for Cancer Management

Review

作者: Swain, Shasank Sekhar ; Dash, Shwetapadma ; Sahoo, Sanjeeb Kumar ; Dutta, Sneha ; Khuntia, Auromira

Cancer is the second-leading cause of death in the 21st century, where early detection and appropriate therapeutic interventions are two components essential for effective cancer management. Despite the availability of several conventional diagnostics and therapeutic agents, cancer mortality rates are rising due to an increase in the frequency of recurrence and metastasis in cancer patients. Therefore, tremendous efforts have been expended to address this significant clinical issue and improve therapeutic efficacy. In this regard, nanotheranostic is a multipotential single platform for both cancer diagnosis and treatment through enhanced aqueous solubility and bioavailability of the encapsulated agent, stimulus responsiveness, tumor-specific targeting ability, precise tumor imaging, and real-time drug delivery. Nonetheless, the translational success of nanotheranostic platforms is still in its infancy and requires more extensive research in the context of tumor heterogeneity, safety profile, and regulatory issues, which pose one of the largest technological limitations. The present review summarizes different nanotheranostic platforms and nanotheranostic candidates in clinical trials (AGuIX® , NBTXR3, Ferumoxtran, MM-398, EndoTAG-1, etc.), along with disadvantages and challenges to improving cancer diagnosis and treatment. Overall, the concept, platform, and technical knowledge of nanotheranostics are really helpful to academic and pharmaceutical researchers.

2024-04-01·Molecular pharmaceutics

Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes

Article

作者: Chen, Guoliang ; Ge, Ruirui ; Wang, Yu ; Han, Chao ; Han, Yingchao ; Sun, Wenliang ; Jiang, Xiaotong ; Yang, Mingshi ; Song, Yanzhi ; Wang, Ning ; Deng, Yihui

Cationic lipids play a pivotal role in developing novel drug delivery systems for diverse biomedical applications, owing to the success of mRNA vaccines against COVID-19 and the Phase III antitumor agent EndoTAG-1. However, the therapeutic potential of these positively charged liposomes is limited by dose-dependent toxicity. While an increased content of cationic lipids in the formulation can enhance the uptake and cytotoxicity toward tumor-associated cells, it is crucial to balance these advantages with the associated toxic side effects. In this work, we synthesized the cationic lipid HC-Y-2 and incorporated it into sialic acid (SA)-modified cationic liposomes loaded with paclitaxel to target tumor-associated immune cells efficiently. The SA-modified cationic liposomes exhibited enhanced binding affinity toward both RAW264.7 cells and 4T1 tumor cells in vitro due to the increased ratios of cationic HC-Y-2 content while effectively inhibiting 4T1 cell lung metastasis in vivo. By leveraging electrostatic forces and ligand-receptor interactions, the SA-modified cationic liposomes specifically target malignant tumor-associated immune cells such as tumor-associated macrophages (TAMs), reduce the proportion of cationic lipids in the formulation, and achieve dual objectives: high cellular uptake and potent antitumor efficacy. These findings highlight the potential advantages of this innovative approach utilizing cationic liposomes.

2022-12-28·ACS applied materials & interfaces

Paclitaxel-Loaded Cationic Fluid Lipid Nanodiscs and Liposomes with Brush-Conformation PEG Chains Penetrate Breast Tumors and Trigger Caspase-3 Activation

Article

作者: Ewert, Kai K. ; Teesalu, Tambet ; Fisher, William S. ; Scodeller, Pablo ; Sidorenko, Valeria ; Steffes, Victoria M. ; Safinya, Cyrus R. ; Simón-Gracia, Lorena

Novel approaches are required to address the urgent need to develop lipid-based carriers of paclitaxel (PTX) and other hydrophobic drugs for cancer chemotherapy. Carriers based on cationic liposomes (CLs) with fluid (i.e., chain-melted) membranes (e.g., EndoTAG-1) have shown promise in preclinical and late-stage clinical studies. Recent work found that the addition of a cone-shaped poly(ethylene glycol)-lipid (PEG-lipid) to PTX-loaded CLs (CLs_PTX) promotes a transition to sterically stabilized, higher-curvature (smaller) nanoparticles consisting of a mixture of PEGylated CLs_PTX and PTX-containing fluid lipid nanodiscs (nanodiscs_PTX). These CLs_PTX and nanodiscs_PTX show significantly improved uptake and cytotoxicity in cultured human cancer cells at PEG coverage in the brush regime (10 mol % PEG-lipid). Here, we studied the PTX loading, in vivo circulation half-life, and biodistribution of systemically administered CLs_PTX and nanodiscs_PTX and assessed their ability to induce apoptosis in triple-negative breast-cancer-bearing immunocompetent mice. We focused on fluid rather than solid lipid nanodiscs because of the significantly higher solubility of PTX in fluid membranes. At 5 and 10 mol % of a PEG-lipid (PEG5K-lipid, molecular weight of PEG 5000 g/mol), the mixture of PEGylated CLs_PTX and nanodiscs_PTX was able to incorporate up to 2.5 mol % PTX without crystallization for at least 20 h. Remarkably, compared to preparations containing 2 and 5 mol % PEG5K-lipid (with the PEG chains in the mushroom regime), the particles at 10 mol % (with PEG chains in the brush regime) showed significantly higher blood half-life, tumor penetration, and proapoptotic activity. Our study suggests that increasing the PEG coverage of CL-based drug nanoformulations can improve their pharmacokinetics and therapeutic efficacy.

项与 EndoTAG-1 相关的新闻（医药）

2019-06-16

·syncorebio.com

SB05PC (EndoTAG®-1) Phase III been Approved in China by NMPA

China NMPA Approves SynCore Biotechnology to Conduct Phase III Human Clinical Trial for SB05PC (EndoTAG®-1), A First-Line Therapy for Pancreatic Cancer Taipei, Taiwan, Jun 16, 2019. SynCore Biotechnology Co. (4192:TT) announces that the company has been approved by China National Medical Products Administration (NMPA) to commence the Phase III human clinical trial for its oncology asset SB05PC (EndoTAG®-1), a novel drug for the first-line treatment of pancreatic cancer. According to World Health Organization (WHO), China holds the highest incidence and mortality of pancreatic cancer, being responsible for 116,300 occurrences and 110,400 deaths in 2018 respectively. The current standard of cares cannot significantly improve the overall survival rate, which leaves a great gap of unmet medical needs. Judging from the results of the completed Phase II study, SB05PC (EndoTAG®-1) shows great potential in prolonging overall survival when compared with Gemcitabine, the standard first-line therapy for pancreatic cancer in China. SB05PC (EndoTAG®-1) shall provide better treatment option and opportunity once been approved in China. SynCore holds diverse and strategic plans for SB05PC (EndoTAG®-1) in different countries. In China, Gemcitabine in the major drug in treating pancreatic cancer, standing for 25% of chemo drug usage. The incidence and mortality rates are also higher in tier 1 cities include Beijing and Shanghai due to highly-struggled lifestyle and intensive pressure. Owing to these, SynCore combines SB05PC (EndoTAG®-1), a cationic liposomal paclitaxel, with gemcitabine in targeting locally advanced and/or metastatic pancreatic cancer for first-line treatment, in comparison with gemcitabine monotherapy. The completed Phase II study shows not only prolonged overall survival but also ameliorated adverse events, which renders higher life quality for pancreatic cancer patients. SynCore will also set study centers at high tier cities in order to accelerate subject enrollment. Paclitaxel and gemcitabine are mature chemo options for various cancer types, both account for top 10 anti-cancer drugs in Chinese public healthcare systems. The annual revenue for these two blockbusters are RMB 5.7 billion and 2.5 billion, ranking as top 1 and top 9 sales in 2017 in Chinese public healthcare systems respectively. Serving as new formulation of paclitaxel, SB05PC (EndoTAG®-1) combines with gemcitabine to target first-line pancreatic cancer treatment, which is a promising new drug in China. SynCore is also actively seeking local partners for co-development and out-licensing for this project. Full News Release Download: Jun 16, 2019: SB05PC (EndoTAG®-1) Phase III been Approved in China by NMPA CONTACT Charles Liang, Investor Relations Phone: +886-2-27640826 Email: finance@syncorebio.com DISCLAIMER This press release may contain certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of SynCore Biotechnology Co., Ltd

临床2期上市批准临床3期

2015-12-21

·BioSpace

Amgen Acquires MediGene AG Spinoff Catherex for $10.5 Million Upfront

December 22, 2015 By Mark Terry , BioSpace.com Breaking News Staff Munich, Germany-based Medigene AG announced yesterday that it had sold its spinoff company, Catherex, Inc. , to Amgen . Medigene , as primary Catherex shareholder, will receive about 40 percent of the payments from Amgen . Catherex shareholders will receive an upfront payment of $10.5 million from Amgen , as well as milestone payments based on Amgen ’s Imlygic, formerly T-Vec. Also, royalty payments on Imlygic will be paid until the end of 2020. Imlygic was approved by the U.S. Food and Drug Administration (FDA) in Oct. 2015 for the treatment of advanced, metastatic melanoma. It was also recently approved in the European Union. “With this transaction we have achieved our goal to profitably realize the previous investments made in Catherex ,” said Peter Llewellyn-Davies , Medigene AG ’s chief financial officer, chief operating officer and managing director, in a statement. “The upfront and milestone payments and the expected cash inflow of regular royalty payments from Amgen is part of our strategy to tap additional financial resources for the ongoing clinical development programs of our innovative immunotherapies.” Catherex is located in Philadelphia. In April 2010, Medigene spun off the company with the development of a cancer-killing herpes simplex virus (oHSV). At that time Medigene received a 40 percent stake in the company. In 2014, Catherex spun off some of its patents and research-and-development programs into a company called Aettis Inc. Medigene holds a 39 percent stake in Aettis. Amgen , which for the most part has stayed out of this year’s merger-and-acquisitions frenzy, indicated in November that they were evaluating acquisition targets in the $10 billion range and in companies that have drugs close to market. The Catherex buy is well shy of the $10 billion range, although it would seem to strengthen Amgen ’s work in the immuno-oncology arena. Catherex is privately-owned, so financial data is not available. Imlygic (taalimogene laherparepvec) was approved by the FDA in October. It is a genetically modified herpes simplex virus type 1 that is engineered to replicate within tumors and manufacture a protein called granulocyte-macrophage colony-stimulating factor (GM-CSF), which causes the cells to rupture, thus releasing tumor-derived antigen. Then, along with GM-CSF, it stimulates an anti-tumor immune response. “This sale of an equity stake to Amgen enables Medigene to commercialize further assets derived from our portfolio,” said Frank Mathias , chief executive officer of Medigene AG and president of Medigene, Inc. , in a statement. “In addition to our recent announcement regarding the transfer of EndoTAG, this step supports Medigene ’s focus on immunotherapy as our core business.” On Dec. 17, Medigene inked a deal with Taiwan-based SynCore Biotechnology Co., Ltd. to sell its EndoTAG platform to SynCore , which replaced and ended a May 2013 license agreement. In addition to 6.3 million euros in licensing payments and proceeds, Medigene received a payment of 5 million euros that will be paid in five annual installments. EndoTag is a composition of neutral and positive lipids. These lipids can be loaded with the cytostatic drug Paclitaxel, which builds the drug candidate EndoTag-1. EndoTag-1 works to attack the blood supply to tumor cells without affecting healthy endothelial tissues.

上市批准引进/卖出免疫疗法并购

100 项与 EndoTAG-1 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期胰腺腺癌	临床3期	美国	杏国新药股份有限公司	2018-10-16
局部晚期胰腺腺癌	临床3期	法国	杏国新药股份有限公司	2018-10-16
局部晚期胰腺腺癌	临床3期	匈牙利	杏国新药股份有限公司	2018-10-16
局部晚期胰腺腺癌	临床3期	以色列	杏国新药股份有限公司	2018-10-16
局部晚期胰腺腺癌	临床3期	俄罗斯	杏国新药股份有限公司	2018-10-16
局部晚期胰腺腺癌	临床3期	中国台湾	杏国新药股份有限公司	2018-10-16
转移性胰腺癌	临床3期	美国	杏国新药股份有限公司	2018-10-16
转移性胰腺癌	临床3期	法国	杏国新药股份有限公司	2018-10-16
转移性胰腺癌	临床3期	匈牙利	杏国新药股份有限公司	2018-10-16
转移性胰腺癌	临床3期	以色列	杏国新药股份有限公司	2018-10-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03126435 (CTgov)	临床3期	胰腺腺癌 \| 转移性胰腺癌 \| 局部晚期胰腺腺癌	218	Gemcitabine+EndoTAG-1 (EndoTAG-1 and Gemcitabine)	鏇蓋齋積顧憲醖積淵淵(網廠艱蓋齋壓淵廠壓醖) = 獵獵願顧構繭顧夢範獵網廠簾範鏇製窪艱願壓 (網餘夢齋餘鏇艱願構鏇, 壓壓糧網選網鏇襯衊觸 ~ 獵膚糧淵醖憲製觸蓋醖) 更多	-	2023-03-24
				Gemcitabine (Gemcitabine Monotherapy)	鏇蓋齋積顧憲醖積淵淵(網廠艱蓋齋壓淵廠壓醖) = 衊積夢獵鑰壓蓋衊選觸網廠簾範鏇製窪艱願壓 (網餘夢齋餘鏇艱願構鏇, 壓選蓋蓋範憲願夢窪餘 ~ 獵繭艱艱顧衊鏇鑰鑰蓋) 更多
ESMO_ASIA2022	临床3期	胰腺腺癌二线	218	EndoTAG-1 plus gemcitabine	膚範顧鑰顧鑰淵衊遞鑰(鬱鹽繭獵範繭醖醖觸憲) = 遞醖壓鏇壓鹹顧鹽鹽窪鑰獵鑰鹽蓋鹽廠顧餘範 (積膚襯築膚積襯膚顧鬱 ) 更多	不佳	2022-12-03
				Gemcitabine alone	膚範顧鑰顧鑰淵衊遞鑰(鬱鹽繭獵範繭醖醖觸憲) = 餘觸窪鏇鏇範衊願鬱艱鑰獵鑰鹽蓋鹽廠顧餘範 (積膚襯築膚積襯膚顧鬱 ) 更多